Clinical Trial

ASCEND: A Study of Cardiovascular Events iN Diabetes

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or death from vascular causes) in patients with diabetes who are not known to have occlusive arterial disease and to assess the effects on serious bleeding or other adverse events.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2005-08-24; most recent amendment 2025-05-16.
Status change: Recruiting → Active, Not Recruiting 2011-08-10
Trial Details
NCT Number NCT00135226
Lead Sponsor University of Oxford
Collaborators: British Heart Foundation, Bayer, Medical Research Council, Solvay Pharmaceuticals, Abbott, Mylan, Health Data Research UK, Alzheimer's Research UK, The Macular Society
Conditions Diabetes Mellitus
Enrollment 15,480 participants
Start Date 2005-03
Primary Completion 2018-03-12 (estimated)
Study Completion 2037-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-28